Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Low-dose naltrexone decreases anxiety, pain, in patients with Fibromyalgia

Tuesday 5 November 2013


From Monthly Prescribing Reference:



Low-Dose Naltrexone Decreases Anxiety, Pain, in Patients with Fibromyalgia

Da Hee Han, PharmD
October 29, 2013

SAN DIEGO, CA—Low-dose naltrexone may be an effective, highly tolerable, and inexpensive treatment for patients with fibromyalgia, according to results of a prospective, open-label study presented at the 2013 ACR/ARHP Annual Meeting.

Fibromyalgia has been classified as a “central sensitivity syndrome” mediated by centrally acting proinflammatory cytokine activity, which can cause symptoms of fibromyalgia.

Noting that a significant number of patients with fibromyalgia do not respond adequately to currently available therapies, Samy Metyas, MD, assistant clinical professor of medicine at University of Southern California, Los Angeles, CA, and colleagues administered naltrexone 3mg at nighttime to 25 patients—24 females and 1 male—diagnosed with fibromyalgia based on American College of Rheumatology criteria. The dose could be titrated to a maximum of 4.5mg. Patients were permitted to continue pregabalin, milnacipran, or duloxetine.

Primary outcome measure was the Revised Fibromyalgia Impact Questionnaire (FIQR) at Month 3; adverse reactions were also recorded.

Of the 22 patients completing the study, 7 (32%) remained on naltrexone monotherapy throughout the study. At Month 3, a 19.5% overall improvement in FIQR was reported. Eleven patients (50%) had an average of a 41% improvement in FIQR.

“The patients reported decreases in anxiety, pain, and sleeping habits from baseline,” Dr. Metyas noted.

Naltrexone is an opioid receptor antagonist used to treat alcohol and opioid dependence. They hypothesized that low-dose naltrexone—an opioid-receptor antagonist used to treat alcohol and opioid dependence—“causes transient blockade of opioid receptors centrally, resulting in a rebound of endorphin function which may attenuate pain in fibromyalgia.”

Further randomized controlled trials and larger studies are needed to further assess the efficacy of naltrexone in fibromyalgia, the investigators concluded.


The above originally appeared here.


Arrow right

More Fibromyalgia News




blog comments powered by Disqus
Previous Previous Page